Corcept Therapeutics vs Xeris Biopharma
CORT and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CORT and XERS compare
Corcept Therapeutics is the larger company, worth 2.5 times as much as Xeris Biopharma ($7.6B against $3.1B).
Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 16.0% for Corcept Therapeutics).
Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −5.1% at Xeris Biopharma.
Corcept Therapeutics scores higher on the StockData Score (11 against 10 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CORT | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $7.6B | $3.1B |
| Share price | $70.07 | $16.80 |
| Change, 1 year | −7.2% | 134% |
| Change, 5 years | 226% | 674% |
| Beta (5Y) | 1.36 | 0.27 |
| Employees | 730 | 435 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 167× | – |
| P/S | 9.1× (better) | 9.1× |
| P/B | 10.7× | – |
| EV/EBITDA | 899× | 84.2× (better) |
| P/FCF | 70.8× | – |
| FCF yield | 1.4% | – |
| Fair value | $11.01 | – |
| Margin of safety | −537% | – |
| Growth | ||
| Revenue growth (TTM) | 16.0% | 36.3% (better) |
| Revenue growth, 5Y average | 16.6% | 70.2% (better) |
| Net income growth (TTM) | −58.7% | – |
| EPS growth (TTM) | −62.5% | – |
| EPS growth, 5Y average | −0.72% | – |
| Profitability | ||
| Gross margin | 98.3% (better) | 86.6% |
| Operating margin | 0.77% | 10.9% (better) |
| Net margin | 6.6% (better) | −5.1% |
| FCF margin | 12.9% | – |
| Return on equity | 8.2% | – |
| Return on invested capital | 1.9% | 22.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 3.45 |
| Interest coverage | – | 1.3× |
| Current ratio | 2.86 (better) | 1.45 |
| Altman Z-score | 27.22 (better) | 3.33 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.56% | – |
| Shareholder yield | 0.56% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 76.2% | 59.4% |
| Held by insiders | 14.4% | 5.2% |
| Insider net buying, 12 months | −$94.0M | −$5.8M (better) |
| Short interest, % of float | 9.9% | 5.2% |
Go deeper
- CORT stock overview
- CORT income statement
- CORT valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.